Literature DB >> 15329391

Dysregulation of gene expression in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse substantia nigra.

Renee M Miller1, Linda M Callahan, Cindy Casaceli, Linlin Chen, Gretchen L Kiser, Buena Chui, Tamma M Kaysser-Kranich, Timothy J Sendera, Chockalingam Palaniappan, Howard J Federoff.   

Abstract

Parkinson's disease pathogenesis proceeds through several phases, culminating in the loss of dopaminergic neurons of the substantia nigra (SN). Although the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of oxidative SN injury is frequently used to study degeneration of dopaminergic neurons in mice and non-human primates, an understanding of the temporal sequence of molecular events from inhibition of mitochondrial complex 1 to neuronal cell death is limited. Here, microarray analysis and integrative data mining were used to uncover pathways implicated in the progression of changes in dopaminergic neurons after MPTP administration. This approach enabled the identification of small, yet consistently significant, changes in gene expression within the SN of MPTP-treated animals. Such an analysis disclosed dysregulation of genes in three main areas related to neuronal function: cytoskeletal stability and maintenance, synaptic integrity, and cell cycle and apoptosis. The discovery and validation of these alterations provide molecular evidence for an evolving cascade of injury, dysfunction, and cell death.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15329391      PMCID: PMC6729635          DOI: 10.1523/JNEUROSCI.4204-03.2004

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  38 in total

1.  14-3-3 inhibition promotes dopaminergic neuron loss and 14-3-3θ overexpression promotes recovery in the MPTP mouse model of Parkinson's disease.

Authors:  H Ding; R Underwood; N Lavalley; T A Yacoubian
Journal:  Neuroscience       Date:  2015-08-24       Impact factor: 3.590

Review 2.  Strategies to unravel molecular codes essential for the development of meso-diencephalic dopaminergic neurons.

Authors:  F M J Jacobs; S M Smits; K J M Hornman; J P H Burbach; M P Smidt
Journal:  J Physiol       Date:  2006-06-29       Impact factor: 5.182

Review 3.  Microarrays in Parkinson's disease: a systematic approach.

Authors:  Renee M Miller; Howard J Federoff
Journal:  NeuroRx       Date:  2006-07

4.  The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements.

Authors:  Leming Shi; Laura H Reid; Wendell D Jones; Richard Shippy; Janet A Warrington; Shawn C Baker; Patrick J Collins; Francoise de Longueville; Ernest S Kawasaki; Kathleen Y Lee; Yuling Luo; Yongming Andrew Sun; James C Willey; Robert A Setterquist; Gavin M Fischer; Weida Tong; Yvonne P Dragan; David J Dix; Felix W Frueh; Frederico M Goodsaid; Damir Herman; Roderick V Jensen; Charles D Johnson; Edward K Lobenhofer; Raj K Puri; Uwe Schrf; Jean Thierry-Mieg; Charles Wang; Mike Wilson; Paul K Wolber; Lu Zhang; Shashi Amur; Wenjun Bao; Catalin C Barbacioru; Anne Bergstrom Lucas; Vincent Bertholet; Cecilie Boysen; Bud Bromley; Donna Brown; Alan Brunner; Roger Canales; Xiaoxi Megan Cao; Thomas A Cebula; James J Chen; Jing Cheng; Tzu-Ming Chu; Eugene Chudin; John Corson; J Christopher Corton; Lisa J Croner; Christopher Davies; Timothy S Davison; Glenda Delenstarr; Xutao Deng; David Dorris; Aron C Eklund; Xiao-hui Fan; Hong Fang; Stephanie Fulmer-Smentek; James C Fuscoe; Kathryn Gallagher; Weigong Ge; Lei Guo; Xu Guo; Janet Hager; Paul K Haje; Jing Han; Tao Han; Heather C Harbottle; Stephen C Harris; Eli Hatchwell; Craig A Hauser; Susan Hester; Huixiao Hong; Patrick Hurban; Scott A Jackson; Hanlee Ji; Charles R Knight; Winston P Kuo; J Eugene LeClerc; Shawn Levy; Quan-Zhen Li; Chunmei Liu; Ying Liu; Michael J Lombardi; Yunqing Ma; Scott R Magnuson; Botoul Maqsodi; Tim McDaniel; Nan Mei; Ola Myklebost; Baitang Ning; Natalia Novoradovskaya; Michael S Orr; Terry W Osborn; Adam Papallo; Tucker A Patterson; Roger G Perkins; Elizabeth H Peters; Ron Peterson; Kenneth L Philips; P Scott Pine; Lajos Pusztai; Feng Qian; Hongzu Ren; Mitch Rosen; Barry A Rosenzweig; Raymond R Samaha; Mark Schena; Gary P Schroth; Svetlana Shchegrova; Dave D Smith; Frank Staedtler; Zhenqiang Su; Hongmei Sun; Zoltan Szallasi; Zivana Tezak; Danielle Thierry-Mieg; Karol L Thompson; Irina Tikhonova; Yaron Turpaz; Beena Vallanat; Christophe Van; Stephen J Walker; Sue Jane Wang; Yonghong Wang; Russ Wolfinger; Alex Wong; Jie Wu; Chunlin Xiao; Qian Xie; Jun Xu; Wen Yang; Liang Zhang; Sheng Zhong; Yaping Zong; William Slikker
Journal:  Nat Biotechnol       Date:  2006-09       Impact factor: 54.908

Review 5.  Finding diamonds in the rubble.

Authors:  Jang-Ho J Cha
Journal:  Exp Neurol       Date:  2007-02-20       Impact factor: 5.330

6.  Gene expression of proteins of the vesicle cycle in the striatum and motor cortex under functional failure of nigrostriatal system.

Authors:  E R Mingazov; M V Ugrumov
Journal:  Dokl Biochem Biophys       Date:  2016-11-06       Impact factor: 0.788

7.  Gene expression of proteins of the vesicle cycle in dopaminergic neurons in modeling of Parkinson's disease.

Authors:  E R Mingazov; M V Ugrumov
Journal:  Dokl Biochem Biophys       Date:  2016-07-15       Impact factor: 0.788

8.  Endogenous dopamine suppresses initiation of swimming in prefeeding zebrafish larvae.

Authors:  Vatsala Thirumalai; Hollis T Cline
Journal:  J Neurophysiol       Date:  2008-06-18       Impact factor: 2.714

9.  Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology.

Authors:  Filip Simunovic; Ming Yi; Yulei Wang; Laurel Macey; Lauren T Brown; Anna M Krichevsky; Susan L Andersen; Robert M Stephens; Francine M Benes; Kai C Sonntag
Journal:  Brain       Date:  2008-12-03       Impact factor: 13.501

Review 10.  Target identification for CNS diseases by transcriptional profiling.

Authors:  C Anthony Altar; Marquis P Vawter; Stephen D Ginsberg
Journal:  Neuropsychopharmacology       Date:  2008-10-15       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.